ANDA 87881, held by Pharmobedient. Lidocaine Hydrochloride.
As of Nov 16, 2026, ANDA 87881 (Lidocaine Hydrochloride), held by Pharmobedient, was first approved by FDA on Nov 18, 1982, with 8 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Lidocaine Hydrochloride Topical Solution is indicated for the production of topical anesthesia of accessible mucous membranes of the oral and nasal cavities and proximal portions of the digestive tract.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Nov 18, 1982 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Lidocaine Hydrochloride4% · solution;topical | Lidocaine Hydrochloride | Rx |
| Oct 19, 2015 | Supplement 12Labeling · Standard review | Approved | None posted |
| Aug 13, 2002 | Supplement 11Manufacturing | Approved | None posted |
| Apr 15, 2002 | Supplement 10Manufacturing | Approved | None posted |
| Feb 16, 1994 | Supplement 9Labeling | Approved | None posted |
| May 28, 1992 | Supplement 8Labeling | Approved | None posted |
| Sep 6, 1989 | Supplement 7Labeling | Approved | None posted |
| May 14, 1987 | Supplement 3Manufacturing | Approved | None posted |
| Oct 6, 1983 | Supplement 1Manufacturing | Approved | None posted |
| Nov 18, 1982 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters